We describe clinical characteristics and deep immunophenotypes in two patients with myelin-oligodendrocyte-glycoprotein (MOG)-antibody-associated-disease after COVID-19. The para-COVID case was a 74-year-old man who developed optic neuritis two days after COVID-19. Immunological assays revealed reduced absolute CD8 T- and B-cell counts with increased frequency of NK cells. Post-COVID case was a 63-year-old man with optic neuritis six months after COVID-19, a frequency of CD8 T-cells was elevated with a relatively low fraction of naïve and a high fraction of effector memory CD8 T-cells. There was increased frequency of CD8CD38HLA-DR T-cells in the para-COVID case; interestingly, CD4CD38HLA-DR T cell frequency was increased in the post-COVID case. Both had increased SARS-CoV-2-specific and MOG-specific T-cell responses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392592 | PMC |
| http://dx.doi.org/10.1016/j.jneuroim.2023.578143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MOG-specific T cell response amplified in para- and post-SAR-CoV-2 infection in myelin oligodendrocyte glycoprotein antibody-associated disease.
J Neuroimmunol
September 2023
Department of Neurology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA; Autoimmunity Center of Excellence, 4015 A. Alfred Taubman Biomedical Sciences Research Building 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA; Michigan Institute for Neurological Disorders, USA. Electronic address:
We describe clinical characteristics and deep immunophenotypes in two patients with myelin-oligodendrocyte-glycoprotein (MOG)-antibody-associated-disease after COVID-19. The para-COVID case was a 74-year-old man who developed optic neuritis two days after COVID-19. Immunological assays revealed reduced absolute CD8 T- and B-cell counts with increased frequency of NK cells.
View Article and Find Full Text PDFComparison of the effectiveness of four SARS-COV-2 v accines in Nuevo Leon, Mexico: A test-negative control study.
Aten Primaria
May 2023
Secretaria de Salud de Nuevo Leon, Monterrey, Nuevo Leon, Mexico. Electronic address:
Objective: The objective of the present study was to provide statewide estimates of real-world effectiveness in reducing the odds of one primary (symptomatic COVID-19 infection) and two secondary outcomes (hospitalization and severe COVID-19 infection) by four vaccines BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), Ad5-nCoV (CanSinoBIO), and CoronaVac (Sinovac Life Sciences), used in Northeast Mexico.
Design: We conducted a test-negative case-control study and analyzed statewide surveillance data from December 2020 to August 2021. SITE: Primary attention and hospitalization.
[PCR for COVID in the transplant protocol].
Rev Med Inst Mex Seguro Soc
January 2023
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad Complementaria Banco de Sangre. Ciudad de México, México.
Background: Since the beginning of the SARS-CoV-2 pandemic, identifying the COVID-19 pathophysiology not only has been addressed to applying diagnostic tests or preventing through vaccines, but also to the timely detection, especially of patients in risk groups such as those in transplants areas (renal, hematology, etcetera). In the case of these patients, using RT-PCR tests avoids putting them at risk by subjecting them to states of immunosuppression that could aggravate their situation if they were faced with an onset of a COVID-19 infection.
Objective: To present the results of patients of a transplant unit tested for SARS-CoV-2.
[Bell's Palsy Secondary to COVID-19 Vaccine Pfizer: Case report].
Rev Med Inst Mex Seguro Soc
March 2022
Instituto Mexicano del Seguro Social, Hospital General de Zona No. 1 "Ignacio García Téllez", Servicio de Medicina Interna. Mérida, Yucatán, México.
Background: BNT162b2 (Pfizer-BioNTech) is a nucleosidemodified mRNA vaccine formulated with lipid nanoparticles for the prevention of COVID-19 disease caused by SARSCoV-2 infection. In early December 2020, BNT162b2 received an emergency use authorization, initial efficacy and safety data have been released, consumer / patient information sheets for vaccines distributed in North America do not warn of Bell's palsy as a possible adverse effect. We reported the case of a patient who developed Bell's palsy on the right side in less than 3 hours after the application of the first dose of the Pfizer-BioNTech COVID-19 vaccine.
View Article and Find Full Text PDFMethods to evaluate COVID-19 vaccine effectiveness, with an emphasis on quasi-experimental approaches.
Cien Saude Colet
November 2021
Centro de Integração de Dados e Conhecimentos para Saúde, Instituto Gonçalo Muniz, Fundação Oswaldo Cruz. Rua Waldemar Falcão 121, Candeal. 40296-710 Salvador BA Brasil.
The evaluation of vaccine effectiveness is conducted with real-world data. They are essential to monitor the performance of vaccination programmes over time, and in the context of the emergence of new variants. Until now, the effectiveness of COVID-19 vaccines has been assessed based on classic methods, such as cohort and test-negative case-control studies, which may often not allow for adequate control of inherent biases in the assignment of vaccination campaigns.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!